STING1 and cancer: A key limitation of current STING agonists is their lack of cell‐ and tissue‐specific targeting, as STING is broadly expressed across immune cells, non‐immune cells (such as endothelial cells), and cancer cells,[34] each of which may exhibit distinct responses to STING activation, ultimately influencing therapeutic outcomes and increasing the risk of immune‐related adverse events.